tradingkey.logo

Boston Scientific Corp

BSX
View Detailed Chart
100.661USD
+0.091+0.09%
Market hours ETQuotes delayed by 15 min
149.01BMarket Cap
53.39P/E TTM

Boston Scientific Corp

100.661
+0.091+0.09%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.09%

5 Days

-1.69%

1 Month

+3.10%

6 Months

-2.15%

Year to Date

+12.70%

1 Year

+19.85%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Boston Scientific Corp's Score

Industry at a Glance

Industry Ranking
2 / 210
Overall Ranking
23 / 4621
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 37 analysts
Buy
Current Rating
125.444
Target Price
+25.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Boston Scientific Corp Highlights

StrengthsRisks
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.75B.
Undervalued
The company’s latest PE is 53.27, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.39B shares, decreasing 0.45% quarter-over-quarter.
Held by PRIMECAP Management
Star Investor PRIMECAP Management holds 34.66M shares of this stock.

Financial Indicators

EPS

No Data

Total revenue

No Data

Boston Scientific Corp Info

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
Ticker SymbolBSX
CompanyBoston Scientific Corp
CEOMr. Michael F. (Mike) Mahoney
Websitehttps://www.bostonscientific.com/en-US/Home.html
KeyAI